A PHASE 2/3 RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY TO EVALUATE THE SAFETY AND EFFICACY OF SUBCUTANEOUS GOLIMUMAB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: PURSUIT SC

(1) U Hospital, Gasthuisberg

(2) U Western Ontario

(3) Janssen R&D, LLC

(4) Biostatistics

(5) CHU

(6) U für Innere Medizin IV

(7) Alfred Hospital

(8) Oregon Health Sciences U

(9) Orebro U Hospital

(10) U of California San Diego



This item was part of the Anti-TNF therapy in IBD session at 20th United European Gastroenterology Week

This item can be cited as: Gut 2012; 61 (Suppl 3) A79